search
Back to results

Comparison of Different Rehabilitation Protocols in Parkinson's Disease With Postural Instability and Gait Disorders

Primary Purpose

Parkinson Disease

Status
Not yet recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Gait and balance training with dual-task + action observation and motor imagery (six weeks)
Gait and balance training with dual-task (six weeks)
Gait and balance training with dual-task + action observation and motor imagery (twelve weeks: 6 + 6)
Gait and balance training with dual-task (twelve weeks: 6 +6)
Sponsored by
Prof. Massimo Filippi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Parkinson Disease focused on measuring Parkinson Disease, Gait, Rehabilitation, Biomarkers, Magnetic resonance imaging

Eligibility Criteria

45 Years - 85 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria for PD patients: 45 years ≤ age ≤ 85 years; Idiopathic PD according to the Movement Disorders Society (MDS) diagnostic criteria Hoehn & Yahr (H&Y) score <= 4 PIGD phenotype Stable dopaminergic medication for at least 4 weeks and without any changes during the observation period (28 weeks) No dementia according to Litvan's criteria and Mini-Mental Status Examination score (MMSE) >= 24 No significant tremor/involuntary movements that could determine artifacts during the MRI acquisition Oral and written informed consent to study participation Inclusion criteria for healthy controls: sex-matched and age-matched (age range: mean age of PD years ± 15 years); oral and written informed consent to study participation Exclusion criteria: Medical conditions or substance abuse that could interfere with cognition; Any major systemic, psychiatric, neurological, visual, and musculoskeletal disturbances or other causes of walking inability; Contraindications to undergoing MRI examination; Brain damage at routine MRI, including lacunae and extensive cerebrovascular disorders; Denied oral and written informed consent to study participation.

Sites / Locations

  • IRCCS San Raffaele
  • Neurology Unit, Azienda Ospedaliera Universitaria Integrata di Verona

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Active Comparator

Experimental

Active Comparator

No Intervention

Arm Label

DUAL-TASK+AOT-MI

DUAL-TASK

DUAL-TASK+AOT-MI_DOUBLE

DUAL-TASK_DOUBLE

Healthy subjects

Arm Description

Dual-task gait and balance training with cognitive facilitations (action observation and motor imagery) for six weeks.

Dual-task gait and balance training with vision of landscape videos for six weeks.

Dual-task gait and balance training with cognitive facilitations (action observation and motor imagery) repeated two times (twelve weeks: 6 + 6).

Dual-task gait and balance training with vision of landscape videos repeated two times (twelve weeks: 6 + 6).

Age- and sex-matched healthy subjects recruited to compare gait, neuropsychological, serum and functional magnetic resonance imaging characteristics at baseline.

Outcomes

Primary Outcome Measures

Total execution time of Timed Up and Go test with cognitive dual-task (TUG-COG)
Changes in time taken to complete the timed up and go test with cognitive dual-task: patients are asked to stand up from a chair, walk for three meters, turn and walk back to the chair while counting backwards by 3 starting from 100. Assessment during ON medication phase.

Secondary Outcome Measures

Total execution time of Timed Up and Go test (TUG)
Changes in time taken to complete the timed up and go test: patients are asked to stand up from a chair, walk for three meters, turn, and walk back to the chair. Assessment during ON medication phase
Total execution time of Timed Up and Go test with manual dual-task (TUG-MAN)
Changes in time taken to complete the timed up and go test with manual dual-task: patients are asked to stand up from a chair, walk for three meters, turn, and walk back to the chair while holding a glass full of water. Assessment during ON medication phase
Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score
MDS-UPDRS evaluates various aspects of Parkinson's disease including non-motor and motor experiences of daily living and motor complications. The MDS-UPDRS contains 65 items divided in four parts (Part I - "non-motor experiences of daily living", Part II - "motor experiences of daily living", Part III - "motor examination", Part IV - "motor complications. Each item is assessed with a 0 to 4 rating system. The total score ranges from 0 to 260 with higher score indicating more severe symptoms. Assessment during ON medication. Only part III assessed also without medication (OFF).
Brain functional changes during functional magnetic resonance imaging (MRI) tasks
Changes in functional MRI brain activity assessed during a motor task, a cognitive task and a dual-task. Assessment during OFF medication phase, at least 12 hours after last medication assumption.
Serum concentration of Neurofilament light chain (NfL)
Serum biomarker of neuroprotection/neurodegeneration
Serum concentration of Glial Fibrillary Acid Protein (GFAP)
Serum biomarker of neuroprotection/neurodegeneration
Serum concentration of Phosphorylated Tau (P-Tau)
Serum biomarker of neuroprotection/neurodegeneration
Serum concentration of Tau
Serum biomarker of neuroprotection/neurodegeneration
Serum concentration of B42
Serum biomarker of neuroprotection/neurodegeneration
Serum concentration of B40
Serum biomarker of neuroprotection/neurodegeneration
Serum concentration of Alpha-synuclein
Serum biomarker of neuroprotection/neurodegeneration
Serum concentration of Brain Derived Neurotrophic Factor (BDNF)
Serum biomarker of neuroprotection/neurodegeneration
Activity Balance Confidence questionnaire (ABC) score
This questionnaire assesses patient-referred balance confidence during 16 daily tasks. Subjects rate their confidence while doing each activity from 0 (no confidence) to 100 (full confidence). Assessment during ON medication phase.
10-meter walk test (10MWT) time
Time taken to walk 10 straight meters. Test performed at comfortable and maximal speed. Assessment during ON medication phase.
Mini Balance Evaluation System Test (MiniBESTest) score
Assessment of different balance systems (anticipatory, reactive postural control, sensory orientation, dynamic gait). MiniBESTest includes 14 items with a score from 0 (severe/unable) to 2 (normal). The maximum score is 28 and a higher score indicates a better balance. Assessment during ON medication phase.
Five-time sit-to-stand (5STS) time
This test measures the amount of time it takes for a patient to stand up and sit down five times in a row, as quickly as possible with arms folded across their chest. Assessment during ON medication phase.
Parkinson's Disease Questionnaire (PDQ-39) score
Parkinson's Disease Questionnaire investigates the quality of life of PD patients. It includes 39 questions with 5 possible answers (never, occasionally, sometimes, often, always) and 8 sub-items related to mobility, activities of daily living, emotional well-being, signs of discouragement, social support, cognitions, communication and bodily discomfort. The maximum score is 100 and a low score is an indicator of a good quality of life. Assessment during ON medication phase.
Stride length
Gait parameter obtained using wearable motion sensors. Assessment during ON medication phase.
Gait velocity
Gait parameter obtained using wearable motion sensors. Assessment during ON medication phase.
Cambridge Neuropsychological Test Automated Battery (CANTAB)
This battery of cognitive tests assesses executive functions, memory and visuospatial abilities. Each subtest of the CANTAB battery provides outcome measures in terms of accuracy (right answers, errors and/or missing answers) and reaction times (highest scores are worse) for every condition within the subtest (the different conditions present with different levels of cognitive load). Assessment during ON medication phase.
Kinesthetic and Visual Imagery Questionnaire (KVIQ)
This questionnaire assesses motor imagery abilities. The Kinesthetic and Visual Imagery Questionnaire (KVIQ) includes 10 items assessing the clarity of the image and the intensity of the sensations that the subject is able to imagine from the first-person perspective (both right and left sides) on a five-point ordinal scale. Total score ranges from 0 to 50 with higher score indicating better motor imagery abilities. Assessment during ON medication phase.
New Freezing of Gait Questionnaire (NFoG-Q)
This is a self-reported questionnaire that measures freezing of gait. It consists of 9 items with a total score ranging from 0 (no freezing) to 28. Higher score indicates worse freezing. Assessment during ON medication phase.

Full Information

First Posted
March 17, 2023
Last Updated
April 3, 2023
Sponsor
Prof. Massimo Filippi
Collaborators
Azienda Ospedaliera Universitaria Integrata Verona
search

1. Study Identification

Unique Protocol Identification Number
NCT05799690
Brief Title
Comparison of Different Rehabilitation Protocols in Parkinson's Disease With Postural Instability and Gait Disorders
Official Title
Multiparametric Biomarkers to Predict the Response to Different Protocols of Motor-cognitive Rehabilitation in Parkinson's Disease Subjects With Postural Instability and Gait Disorders
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
April 10, 2023 (Anticipated)
Primary Completion Date
January 10, 2026 (Anticipated)
Study Completion Date
April 10, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Prof. Massimo Filippi
Collaborators
Azienda Ospedaliera Universitaria Integrata Verona

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of the study is to compare the effects of 2 different dosages and modalities of motor-cognitive rehabilitation in Parkinson's disease with postural instability and gait disorders (PD-PIGD) on clinical features, neuroimaging and blood-based biomarkers at short-term (2 months) and long-term (7 months) follow-up. Fifty subjects with PD-PIGD will be randomized in 2 training groups: DUAL-TASK+AOT-MI and the DUAL-TASK groups. The DUAL-TASK+AOT-MI group will perform a dual-task gait/balance training consisting of action observation training (AOT) and motor imagery (MI) combined with practicing the observed-imagined exercises; DUAL-TASK group will perform the same exercises combined with watching landscape videos. The training will last 6 weeks, 3 times/week, 1 hour per session. Before and after training (W6), all the patients will undergo neurological, gait/balance, cognitive/behavioral, magnetic resonance imaging (MRI) and serum biomarkers evaluations. Neurological, gait/balance, cognitive/behavioral assessments and serum biomarkers will be also repeated at the 14-week follow-up (W14) to assess maintenance of results. Patients of both DUAL-TASK+AOT-MI and DUAL-TASK groups will be further randomized to repeat the training (6 weeks, 3 times/week, 1 hour each session) starting at W14 (DUAL-TASK+AOT-MI_DOUBLE and DUAL-TASK_DOUBLE groups). After six weeks (W20) all the subjects repeating the training will be evaluated (neurological, gait/balance, cognitive/behavioral assessments). At 28-week follow-up (W28), the whole sample of patients will be assessed with neurological, gait/balance, cognitive/behavioral, MRI and serum biomarkers evaluations. All MRI scans will be acquired at least 12 hours after last dopaminergic therapy administration to mitigate the pharmacological effects on neural activity. Twenty age- and sex-matched healthy controls will be recruited to perform gait/balance and cognitive/behavioral assessments, blood sample and brain MRI acquisition at baseline. The secondary aims of the study are to define the neuroimaging and blood-based biomarkers of PD-PIGD patients presenting different clinical features (e.g. presence of mild cognitive impairment, freezing of gait, falls and mood disturbances) and to evaluate the role of blood-based and neuroimaging biomarkers, together with clinical characteristics, in predicting the response to different dosages of rehabilitation in PD-PIGD throughout the development of a machine-learning algorithm.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease
Keywords
Parkinson Disease, Gait, Rehabilitation, Biomarkers, Magnetic resonance imaging

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Single-blind randomized controlled trial. Fifty PD patients are randomly divided into two groups: 25 in DUAL-TASK+AOT-MI (experimental) and 25 in the DUAL-TASK (active comparator). Half of the patients are further randomized to repeat the treatment (DUAL-TASK+AOT-MI_DOUBLE and DUAL-TASK_DOUBLE). The assessors are blinded to the group allocation. In addition, a group of 20 healthy age- and sex-matched control is included at baseline
Masking
Outcomes Assessor
Masking Description
Physiotherapist, neurologists, neuropsychologists and radiologist assessing the patients are blinded to group allocation.
Allocation
Randomized
Enrollment
70 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
DUAL-TASK+AOT-MI
Arm Type
Experimental
Arm Description
Dual-task gait and balance training with cognitive facilitations (action observation and motor imagery) for six weeks.
Arm Title
DUAL-TASK
Arm Type
Active Comparator
Arm Description
Dual-task gait and balance training with vision of landscape videos for six weeks.
Arm Title
DUAL-TASK+AOT-MI_DOUBLE
Arm Type
Experimental
Arm Description
Dual-task gait and balance training with cognitive facilitations (action observation and motor imagery) repeated two times (twelve weeks: 6 + 6).
Arm Title
DUAL-TASK_DOUBLE
Arm Type
Active Comparator
Arm Description
Dual-task gait and balance training with vision of landscape videos repeated two times (twelve weeks: 6 + 6).
Arm Title
Healthy subjects
Arm Type
No Intervention
Arm Description
Age- and sex-matched healthy subjects recruited to compare gait, neuropsychological, serum and functional magnetic resonance imaging characteristics at baseline.
Intervention Type
Behavioral
Intervention Name(s)
Gait and balance training with dual-task + action observation and motor imagery (six weeks)
Intervention Description
Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI. 1 hour, 3 times a week for six weeks.
Intervention Type
Behavioral
Intervention Name(s)
Gait and balance training with dual-task (six weeks)
Intervention Description
Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution. 1 hour, 3 times a week for six weeks.
Intervention Type
Behavioral
Intervention Name(s)
Gait and balance training with dual-task + action observation and motor imagery (twelve weeks: 6 + 6)
Intervention Description
Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing a balance or gait task (action observation - AOT) and will imagine the same exercise (motor-imagery - MI) before task execution. Each training session will be proposed with the following modality: 2 minutes of AOT - 5 minutes of task execution - 2 minutes of MI - 5 minutes of task execution. Patients will be explicitly asked to concentrate on how the actions are performed in the videos and to carefully use MI to improve their motor performance. Patients will not be allowed to perform any movement while watching videos or during MI. The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14) 1 hour, 3 times a week for twelve weeks (6+6).
Intervention Type
Behavioral
Intervention Name(s)
Gait and balance training with dual-task (twelve weeks: 6 +6)
Intervention Description
Increasingly difficult gait and balance exercises up to include dual-task. During each training session, four exercises (5 minutes of execution, two times each) will be proposed. Patients will observe a 2-minute video clip showing static landscapes before task execution. Each training session will be proposed with the following modality: 2 minutes of videos - 5 minutes of task execution - 2 minutes of videos - 5 minutes of task execution. The training protocol will be repeated two times: once starting at baseline, once starting after the first follow-up at week 14 (W14) 1 hour, 3 times a week for twelve weeks (6+6).
Primary Outcome Measure Information:
Title
Total execution time of Timed Up and Go test with cognitive dual-task (TUG-COG)
Description
Changes in time taken to complete the timed up and go test with cognitive dual-task: patients are asked to stand up from a chair, walk for three meters, turn and walk back to the chair while counting backwards by 3 starting from 100. Assessment during ON medication phase.
Time Frame
Baseline, week 6, week 14 and week 28. At week 20 only for patients repeating the training.
Secondary Outcome Measure Information:
Title
Total execution time of Timed Up and Go test (TUG)
Description
Changes in time taken to complete the timed up and go test: patients are asked to stand up from a chair, walk for three meters, turn, and walk back to the chair. Assessment during ON medication phase
Time Frame
Baseline, week 6, week 14 and week 28. At week 20 only for patients repeating the training.
Title
Total execution time of Timed Up and Go test with manual dual-task (TUG-MAN)
Description
Changes in time taken to complete the timed up and go test with manual dual-task: patients are asked to stand up from a chair, walk for three meters, turn, and walk back to the chair while holding a glass full of water. Assessment during ON medication phase
Time Frame
Baseline, week 6, week 14 and week 28. At week 20 only for patients repeating the training.
Title
Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score
Description
MDS-UPDRS evaluates various aspects of Parkinson's disease including non-motor and motor experiences of daily living and motor complications. The MDS-UPDRS contains 65 items divided in four parts (Part I - "non-motor experiences of daily living", Part II - "motor experiences of daily living", Part III - "motor examination", Part IV - "motor complications. Each item is assessed with a 0 to 4 rating system. The total score ranges from 0 to 260 with higher score indicating more severe symptoms. Assessment during ON medication. Only part III assessed also without medication (OFF).
Time Frame
Baseline, week 6, week 14 and week 28. At week 20 only for patients repeating the training.
Title
Brain functional changes during functional magnetic resonance imaging (MRI) tasks
Description
Changes in functional MRI brain activity assessed during a motor task, a cognitive task and a dual-task. Assessment during OFF medication phase, at least 12 hours after last medication assumption.
Time Frame
Baseline, week 6 and week 28
Title
Serum concentration of Neurofilament light chain (NfL)
Description
Serum biomarker of neuroprotection/neurodegeneration
Time Frame
Baseline, week 6, week 14 and week 28.
Title
Serum concentration of Glial Fibrillary Acid Protein (GFAP)
Description
Serum biomarker of neuroprotection/neurodegeneration
Time Frame
Baseline, week 6, week 14 and week 28.
Title
Serum concentration of Phosphorylated Tau (P-Tau)
Description
Serum biomarker of neuroprotection/neurodegeneration
Time Frame
Baseline, week 6, week 14 and week 28.
Title
Serum concentration of Tau
Description
Serum biomarker of neuroprotection/neurodegeneration
Time Frame
Baseline, week 6, week 14 and week 28.
Title
Serum concentration of B42
Description
Serum biomarker of neuroprotection/neurodegeneration
Time Frame
Baseline, week 6, week 14 and week 28.
Title
Serum concentration of B40
Description
Serum biomarker of neuroprotection/neurodegeneration
Time Frame
Baseline, week 6, week 14 and week 28.
Title
Serum concentration of Alpha-synuclein
Description
Serum biomarker of neuroprotection/neurodegeneration
Time Frame
Baseline, week 6, week 14 and week 28.
Title
Serum concentration of Brain Derived Neurotrophic Factor (BDNF)
Description
Serum biomarker of neuroprotection/neurodegeneration
Time Frame
Baseline, week 6, week 14 and week 28.
Title
Activity Balance Confidence questionnaire (ABC) score
Description
This questionnaire assesses patient-referred balance confidence during 16 daily tasks. Subjects rate their confidence while doing each activity from 0 (no confidence) to 100 (full confidence). Assessment during ON medication phase.
Time Frame
Baseline, week 6, week 14 and week 28. At week 20 only for patients repeating the training.
Title
10-meter walk test (10MWT) time
Description
Time taken to walk 10 straight meters. Test performed at comfortable and maximal speed. Assessment during ON medication phase.
Time Frame
Baseline, week 6, week 14 and week 28. At week 20 only for patients repeating the training.
Title
Mini Balance Evaluation System Test (MiniBESTest) score
Description
Assessment of different balance systems (anticipatory, reactive postural control, sensory orientation, dynamic gait). MiniBESTest includes 14 items with a score from 0 (severe/unable) to 2 (normal). The maximum score is 28 and a higher score indicates a better balance. Assessment during ON medication phase.
Time Frame
Baseline, week 6, week 14 and week 28. At week 20 only for patients repeating the training.
Title
Five-time sit-to-stand (5STS) time
Description
This test measures the amount of time it takes for a patient to stand up and sit down five times in a row, as quickly as possible with arms folded across their chest. Assessment during ON medication phase.
Time Frame
Baseline, week 6, week 14 and week 28. At week 20 only for patients repeating the training.
Title
Parkinson's Disease Questionnaire (PDQ-39) score
Description
Parkinson's Disease Questionnaire investigates the quality of life of PD patients. It includes 39 questions with 5 possible answers (never, occasionally, sometimes, often, always) and 8 sub-items related to mobility, activities of daily living, emotional well-being, signs of discouragement, social support, cognitions, communication and bodily discomfort. The maximum score is 100 and a low score is an indicator of a good quality of life. Assessment during ON medication phase.
Time Frame
Baseline, week 6, week 14 and week 28. At week 20 only for patients repeating the training.
Title
Stride length
Description
Gait parameter obtained using wearable motion sensors. Assessment during ON medication phase.
Time Frame
Baseline, week 6, week 14 and week 28. At week 20 only for patients repeating the training.
Title
Gait velocity
Description
Gait parameter obtained using wearable motion sensors. Assessment during ON medication phase.
Time Frame
Baseline, week 6, week 14 and week 28. At week 20 only for patients repeating the training.
Title
Cambridge Neuropsychological Test Automated Battery (CANTAB)
Description
This battery of cognitive tests assesses executive functions, memory and visuospatial abilities. Each subtest of the CANTAB battery provides outcome measures in terms of accuracy (right answers, errors and/or missing answers) and reaction times (highest scores are worse) for every condition within the subtest (the different conditions present with different levels of cognitive load). Assessment during ON medication phase.
Time Frame
Baseline, week 6, week 14 and week 28. At week 20 only for patients
Title
Kinesthetic and Visual Imagery Questionnaire (KVIQ)
Description
This questionnaire assesses motor imagery abilities. The Kinesthetic and Visual Imagery Questionnaire (KVIQ) includes 10 items assessing the clarity of the image and the intensity of the sensations that the subject is able to imagine from the first-person perspective (both right and left sides) on a five-point ordinal scale. Total score ranges from 0 to 50 with higher score indicating better motor imagery abilities. Assessment during ON medication phase.
Time Frame
Baseline, week 6 and week 28.
Title
New Freezing of Gait Questionnaire (NFoG-Q)
Description
This is a self-reported questionnaire that measures freezing of gait. It consists of 9 items with a total score ranging from 0 (no freezing) to 28. Higher score indicates worse freezing. Assessment during ON medication phase.
Time Frame
Baseline, week 6, week 14 and week 28. At week 20 only for patients

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria for PD patients: 45 years ≤ age ≤ 85 years; Idiopathic PD according to the Movement Disorders Society (MDS) diagnostic criteria Hoehn & Yahr (H&Y) score <= 4 PIGD phenotype Stable dopaminergic medication for at least 4 weeks and without any changes during the observation period (28 weeks) No dementia according to Litvan's criteria and Mini-Mental Status Examination score (MMSE) >= 24 No significant tremor/involuntary movements that could determine artifacts during the MRI acquisition Oral and written informed consent to study participation Inclusion criteria for healthy controls: sex-matched and age-matched (age range: mean age of PD years ± 15 years); oral and written informed consent to study participation Exclusion criteria: Medical conditions or substance abuse that could interfere with cognition; Any major systemic, psychiatric, neurological, visual, and musculoskeletal disturbances or other causes of walking inability; Contraindications to undergoing MRI examination; Brain damage at routine MRI, including lacunae and extensive cerebrovascular disorders; Denied oral and written informed consent to study participation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elisabetta Sarasso, MSc, PT
Phone
0226434685
Ext
0039
Email
sarasso.elisabetta@hsr.it
First Name & Middle Initial & Last Name or Official Title & Degree
Roberta Balestrino, MD
Phone
0226436168
Ext
0039
Email
balestrino.roberta@hstr.it
Facility Information:
Facility Name
IRCCS San Raffaele
City
Milan
ZIP/Postal Code
20132
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Massimo Filippi, Prof, MD
Phone
0226433054
Ext
0039
Email
filippi.massimo@hsr.it
Facility Name
Neurology Unit, Azienda Ospedaliera Universitaria Integrata di Verona
City
Verona
ZIP/Postal Code
37126
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michele Tinazzi, Prof, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Comparison of Different Rehabilitation Protocols in Parkinson's Disease With Postural Instability and Gait Disorders

We'll reach out to this number within 24 hrs